109899-62-9

Basic information

• Product Name: 2-(4-methoxy-phenylamino)-3-nitro-benzoic acid methyl ester
• Synonyms: 2-(4-methoxy-phenylamino)-3-nitro-benzoic acid methyl ester
• CAS NO: 109899-62-9
• Molecular Weight: 302.287
• Mol File: 109899-62-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(4-methoxy-phenylamino)-3-nitro-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-methoxy-phenylamino)-3-nitro-benzoic acid methyl ester(109899-62-9)
• EPA Substance Registry System: 2-(4-methoxy-phenylamino)-3-nitro-benzoic acid methyl ester(109899-62-9)

Safety Data

• Hazardous Substances Data: 109899-62-9(Hazardous Substances Data)

Upstream product

• 5337-09-7 2-bromo-3-nitro-benzoic acid methyl ester 
• 104-94-9 4-methoxy-aniline 
• 573-54-6 2-bromo-3-nitro-benzoic acid 

Downstream Products

• 38120-53-5 2-((4-methoxyphenyl)amino)-3-nitrobenzoic acid 

Relevant articles and documents

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.